Travere Therapeutics Provides Corporate Update and 2025 Outlook
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net ...
Travere Therapeutics sees FY24 net product sales approx $227M
The Company ended 2024 with approximately $371 million in cash, cash equivalents, and marketable securities. The Company also provided an ...
pharmaphorum1d
CSL, Travere close on EU approval of IgAN drug sparsentan
Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...
Seeking Alpha25d
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues.
Medindia1mon
Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan
TOKYO, Dec. 2, 2024 /PRNewswire/ -- Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Travere") and ...
Pharmabiz1mon
UK MHRA grants marketing authorization to sparsentan to treat adult patients with primary immunoglobulin A nephropathy
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy (IgAN). IgA neuropathy, also known as ...
Yahoo Finance1mon
Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan
TOKYO, Dec. 2, 2024 /PRNewswire/ -- Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Travere") and ...